Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Stathmin-2 pre-mRNA (STMN2 pre-mRNA)
- Target
- STMN2 pre-mRNA
- Molecular classification
- Other (pre-mRNA), RNA precursor
01
Overview
Stathmin-2 pre-mRNA is the precursor RNA transcript for the Stathmin-2 protein (also known as SCG10), an essential regulator of microtubule dynamics involved in axonal outgrowth, regeneration, and maintenance[2][3][6][8]. Proper processing of this pre-mRNA is crucial for neuronal health, as misregulation—most notably due to nuclear loss of TDP-43—leads to cryptic splicing and premature polyadenylation, resulting in truncated, non-functional mRNA and loss of Stathmin-2 protein[1][3][4][5]. This pathological mechanism is associated with amyotrophic lateral sclerosis and other neurodegenerative conditions. Therapeutic strategies, such as antisense oligonucleotides, seek to correct aberrant splicing of Stathmin-2 pre-mRNA and restore protein function[5][7]. STMN2 pre-mRNA itself, as a direct target of RNA-based therapies, is recognized as a novel therapeutic target in neurodegeneration research.
- Other names
- SCG10 pre-mRNAStathmin-2 precursor mRNA
02
Mechanism of action
Correction of aberrant splicing/polyadenylation, Restoration of full-length protein expression
03
Biological functions
Regulation of microtubule dynamicsAxonal growth and regenerationNeurite outgrowth
04
Disease associations
Neurodegenerative disease (especially amyotrophic lateral sclerosis, ALS)Other neuronal injuryAxonal degeneration
05
Safety considerations
Off-target effects of RNA-targeting agentsDisruption of normal neuronal RNA splicingPotential impact on essential neuronal functions
06
Interacting drugs
Antisense oligonucleotides (experimental)
1 more in the full profile.
07
Biomarkers
STMN2 mRNA levels (especially full-length vs. truncated isoforms)Cryptic exon inclusion as marker of TDP-43 dysfunction
Beyond the preview
Go deeper on Stathmin-2 pre-mRNA (STMN2 pre-mRNA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Stathmin-2 pre-mRNA (STMN2 pre-mRNA).